^
2d
Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (clinicaltrials.gov)
P=N/A, N=100, Recruiting, University of Chicago | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
Trial completion date • Trial primary completion date
9d
Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide. (PubMed, Case Rep Oncol Med)
A 75-year-old man with mHSPC was treated with Apa and leuprorelin. Apa induced CYP3A4 via the PXR pathway, leading to a sustained DDI with CsA. Careful monitoring is necessary when Apa is coadministered with CYP3A4 substrates.
Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
apalutamide • cyclosporine • leuprolide acetate for depot suspension
11d
Trial completion
|
goserelin acetate
17d
COMPASS - COpenhagen MenoPAuSe Study (2025-522558-37-00)
P1/2, N=200, Not yet recruiting, Region Hovedstaden
New P1/2 trial
|
triptorelin
19d
A single biomarker may not yield a reliable binary clinical answer: B cell lymphoma 6 testing and resulting interventions for endometriosis in infertility care. (PubMed, F S Rep)
Of the patients treated for their positive BCL6 results, 20 (86%) were treated with leuprolide acetate, 9 (39%) with an aromatase inhibitor, and 1 (4%) was surgically managed with a laparoscopy in preparation for their frozen embryo transfer...The relationship between BCL6 and endometriosis may not be the golden solution to a single marker focus for testing, or for subsequent therapy planning among infertility patients. Clinicians should be cautious in using single marker testing for diagnosing and treating endometriosis in patients without strong additional therapeutic evidence.
Journal
|
BCL6 (B-cell CLL/lymphoma 6)
|
leuprolide acetate for depot suspension
21d
Trial completion
|
Eligard (leuprolide acetate)
24d
Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients (clinicaltrials.gov)
P2/3, N=119, Completed, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Completed | Trial completion date: Sep 2026 --> Sep 2025
Trial completion • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • HER-2 expression
|
cyclophosphamide • epirubicin • exemestane • AiRuiKang (dalpiciclib) • goserelin acetate
29d
SATURN: Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer (clinicaltrials.gov)
P2, N=28, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
Trial completion date • Trial primary completion date
|
abiraterone acetate • Eligard (leuprolide acetate) • apalutamide • Viadur (leuprorelin implant)
1m
Study on the Improvement Effect of Probiotics on Perimenopausal Syndrome in Women with Infertility Induced by Leuprolide (ChiCTR2600117205)
P=N/A, N=100, Not yet recruiting, Reproductive Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine; Reproductive Hospital Affiliated to Jiangxi University of Trad
New trial
|
leuprolide acetate for depot suspension
1m
Comparison of Outcomes Between the GnRH-Agonist Long Protocol and the Intensified Estrogen Protocol for Treating Thin Endometrium in Frozen Embryo Transfer Cycles (ChiCTR2500113652)
P=N/A, N=282, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
New trial
1m
Multidimensional evaluation of different dosage forms of goserelin in the treatment of premenopausal HR+ breast cancer patients based on real-world data (ChiCTR2500112684)
P=N/A, N=200, Recruiting, First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University
New trial
|
PGR (Progesterone receptor)
|
goserelin acetate
1m
A randomized crossover trial on the preference of different preparations of goserelin for androgen deprivation therapy (ADT) in patients with prostate cancer (ChiCTR2500111711)
P=N/A, N=60, Recruiting, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
New trial
|
goserelin acetate